trial

Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.

NCTId NCT07047651
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Active Not Recruiting
Enrollment 84 (actual)
Sponsored by Dr. Stavroula Rakitzi
Primary completion 2027-12-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Active Not Recruiting
Enrollment
84 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2025-06-04
Primary completion
2027-12-20
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
—

Sponsors

Dr. Stavroula RakitziLead Sponsor

Investigators

2
Dr. Stavroula Rakitzi, PhDStudy Director
Dr. Polyxeni Georgila, M. D.Study Director

Sites

1 total
Athens, Greece

Facts & assertions

4 sourced
Enrollment
84
Phase
PHASE4
Primary Completion Date
2027-12-20
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
lead_sponsor
Dr. Stavroula Rakitzi
company
indication
Treatment Resistant Schizophrenia
indication
Schizophrenia, Treatment-Resistant
indication
Treatment Resistant Bipolar Disorder
indication
investigator
Dr. Stavroula Rakitzi, PhD
person
Dr. Polyxeni Georgila, M. D.
person